Notice of Special Interest (NOSI): The HIV-HCV-Substance Use Disorder Syndemic: Therapeutic Approaches
notice number: not-da-20-032key dates release date: february 21, 2020 first available due date: june 05, 2020 expiration date: september 08, 2023pa-19-055, research project grant (parent r01 clinical trial required)pa-19-056, nih research project grant (parent r01 clinical trial not allowed)pa-19-091, nih research project grant (parent r01 basic experimental studies with humans required)issued by national institute on drug abuse (nida)purposethe purpose of this notice is to communicate the national institute on drug abuse's (nida) interest in advancing the development of pharmacological and non-pharmacological interventions for the hiv /hcv/ substance use disorders (sud) syndemic. the ultimate goal of this endeavor is to reduce the burden of hiv/hcv/sud by discovering safe and effective therapeutic approaches for these health conditions.background:syndemic (synergistic epidemic) is the aggregation of two or more, concurrent or sequential epidemics or disease clusters, interacting synergistically in a population, contributing to excess burden of disease and prognosis. people who inject drugs (pwid) are at high risk of developing chronic bloodborne infectious disorders, among them hiv and hcv, with notorious morbidity and mortality rates. in spite of major advances in the treatment of hiv, hcv and sud, a substantial number of pwid perpetuates hiv and hcv epidemics, particularly in the most vulnerable populations. therefore, the syndemic of hiv/hcv/sud is a significant public health concern.although research to date has focused on the treatment of each individual condition, a growing body of knowledge indicates that the concurrent syndromic presence is difficult to treat and has worse prognosis. thus, the development of safe and effective treatments for this syndemic condition is a high public health priority.research objectives:nida is interested in receiving research applications focusing on studying the safety and efficacy of medications to treat the triple comorbidity of hiv/hcv/sud.this nosi encourages, but is not limited to, research applications in the following areas:application and submission informationthis notice applies to due dates on or after june 5, 2020 and subsequent receipt dates through september 8, 2023.submit applications for this initiative using one of the following funding opportunity announcements (foas) or any reissues of these announcement through the expiration date of this notice.all instructions in the sf424 (r&r) application guide and the funding opportunity announcement used for submission must be followed, with the following additions:inquiriesscientific/research contact(s)raul mandler, md; faan; fana national institute on drug abuse (nida) telephone: 301-480-2541 email: mandlerr@nih.gov weekly toc for this announcement nih funding opportunities and noticesnote: for help accessing pdf, rtf, ms word, excel, powerpoint, audio or video files, see help downloading files.